RxSight announces CFO Shelley Thunen's transition, effective by January 31, 2026, continuing as a consultant post-transition.
Quiver AI Summary
RxSight, Inc., an ophthalmic medical device company focused on customized vision solutions post-cataract surgery, announced the transition of Shelley Thunen from her role as Chief Financial Officer. She will stay with the company until her successor is appointed or until January 31, 2026, and will continue to support RxSight as a consultant afterward. CEO Ron Kurtz and Chairman Andy Corley both praised Thunen for her significant contributions, highlighting her impact on the company's financial strategy and growth, including its successful IPO in 2021. RxSight is known for its innovative Light Adjustable Lens system, which allows for post-surgery adjustments to enhance patient vision.
Potential Positives
- RxSight acknowledges the significant contributions of Shelley Thunen, the departing Chief Financial Officer, highlighting her integral role in the company's growth and success over nearly a decade.
- The company has shown a commitment to continuity by having Shelley Thunen remain until her successor is appointed, ensuring stability during the transition period.
- Shelley Thunen’s transition to a consulting role indicates her ongoing involvement, suggesting a retained depth of knowledge and guidance that will benefit the company moving forward.
Potential Negatives
- Transition of a key executive, such as the Chief Financial Officer, may raise concerns about continuity and stability within the company's leadership team during a critical period.
- The announcement could indicate potential challenges in the company's financial strategy or operations, leading to speculation among investors regarding the reasons for the CFO's departure.
- The need to find and transition to a new CFO could temporarily distract the company from its core operations and impact decision-making processes at a pivotal time.
FAQ
Who is transitioning from their role at RxSight?
Shelley Thunen, the Chief Financial Officer of RxSight, is transitioning from her role.
What will Shelley Thunen's role be after the transition?
After the transition, Shelley Thunen will serve as a consultant for RxSight.
What has been Shelley's impact on RxSight?
Shelley has played a key role in guiding RxSight's financial strategy and growth over nearly a decade.
What products does RxSight, Inc. offer?
RxSight offers the RxSight® Light Adjustable Lens system, the first adjustable intraocular lens post-surgery.
How can I find more information about RxSight?
Additonal information about RxSight can be found at their official website, www.rxsight.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RXST Revenue
$RXST had revenues of $30.3M in Q3 2025. This is a decrease of -14.09% from the same period in the prior year.
You can track RXST financials on Quiver Quantitative's RXST stock page.
$RXST Hedge Fund Activity
We have seen 90 institutional investors add shares of $RXST stock to their portfolio, and 141 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 3,702,967 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $33,289,673
- MILLENNIUM MANAGEMENT LLC added 1,241,885 shares (+130.6%) to their portfolio in Q3 2025, for an estimated $11,164,546
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 888,950 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,991,660
- CREDIT AGRICOLE S A removed 786,063 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,066,706
- WELLINGTON MANAGEMENT GROUP LLP removed 727,952 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,544,288
- BANK OF AMERICA CORP /DE/ added 579,653 shares (+406.0%) to their portfolio in Q3 2025, for an estimated $5,211,080
- TWO SIGMA ADVISERS, LP added 548,800 shares (+302.5%) to their portfolio in Q3 2025, for an estimated $4,933,712
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RXST Analyst Ratings
Wall Street analysts have issued reports on $RXST in the last several months. We have seen 1 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 11/06/2025
- JP Morgan issued a "Underweight" rating on 11/06/2025
- B of A Securities issued a "Underperform" rating on 07/09/2025
To track analyst ratings and price targets for $RXST, check out Quiver Quantitative's $RXST forecast page.
$RXST Price Targets
Multiple analysts have issued price targets for $RXST recently. We have seen 9 analysts offer price targets for $RXST in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Patrick Wood from Morgan Stanley set a target price of $10.0 on 12/02/2025
- Larry Biegelsen from Wells Fargo set a target price of $10.0 on 11/06/2025
- David Saxon from Needham set a target price of $12.0 on 11/06/2025
- Robbie Marcus from JP Morgan set a target price of $9.0 on 11/06/2025
- Tom Stephan from Stifel set a target price of $8.0 on 08/08/2025
- Danielle Antalffy from UBS set a target price of $8.0 on 08/08/2025
- Young Li from Jefferies set a target price of $9.0 on 07/10/2025
Full Release
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company’s Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.
“Shelley has been a key and trusted partner throughout some of the most important years in RxSight’s development,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “Shelley developed and executed on our financial strategy, and over nearly a decade, her leadership and unwavering commitment helped guide RxSight from a pre-commerical company to one with more than 1,100 LDDs in the field and over a quarter million procedures performed. She has shaped the foundation we rely on today, and we are truly grateful for everything she has done for our patients, our customers, and everyone at RxSight.”
“Shelley has had a profound impact on RxSight,” said Andy Corley, Chairman of the Board. “Her judgment, integrity, and dedication helped guide the Company through pivotal events, including our initial public offering in 2021, and positioned RxSight for the opportunities ahead. The Board is sincerely appreciative of her service and the lasting mark she leaves on the organization.”
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight ® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens ® (LAL ® /LAL+ ® , collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com .
Company Contact:
Shelley B. Thunen
Chief Financial Officer
[email protected]
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
[email protected]
